Cargando…

NK Cell-Based Immunotherapy in Cancer Metastasis

Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzo-Herrero, Seila, López-Soto, Alejandro, Sordo-Bahamonde, Christian, Gonzalez-Rodriguez, Ana P, Vitale, Massimo, Gonzalez, Segundo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357056/
https://www.ncbi.nlm.nih.gov/pubmed/30597841
http://dx.doi.org/10.3390/cancers11010029
_version_ 1783391706383646720
author Lorenzo-Herrero, Seila
López-Soto, Alejandro
Sordo-Bahamonde, Christian
Gonzalez-Rodriguez, Ana P
Vitale, Massimo
Gonzalez, Segundo
author_facet Lorenzo-Herrero, Seila
López-Soto, Alejandro
Sordo-Bahamonde, Christian
Gonzalez-Rodriguez, Ana P
Vitale, Massimo
Gonzalez, Segundo
author_sort Lorenzo-Herrero, Seila
collection PubMed
description Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic efficacy, especially in solid tumors and metastases, still need to be solved. Moreover, immunotherapeutic strategies have mainly focused on modulating the activity of T cells, while Natural Killer (NK) cells have only recently been taken into consideration. NK cells represent an attractive target for cancer immunotherapy owing to their innate capacity to eliminate malignant tumors in a non-Major Histocompatibility Complex (MHC) and non-tumor antigen-restricted manner. In this review, we analyze the mechanisms and efficacy of NK cells in the control of metastasis and we detail the immunosubversive strategies developed by metastatic cells to evade NK cell-mediated immunosurveillance. We also share current and cutting-edge clinical approaches aimed at unleashing the full anti-metastatic potential of NK cells, including the adoptive transfer of NK cells, boosting of NK cell activity, redirecting NK cell activity against metastatic cells and the release of evasion mechanisms dampening NK cell immunosurveillance.
format Online
Article
Text
id pubmed-6357056
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63570562019-02-05 NK Cell-Based Immunotherapy in Cancer Metastasis Lorenzo-Herrero, Seila López-Soto, Alejandro Sordo-Bahamonde, Christian Gonzalez-Rodriguez, Ana P Vitale, Massimo Gonzalez, Segundo Cancers (Basel) Review Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic efficacy, especially in solid tumors and metastases, still need to be solved. Moreover, immunotherapeutic strategies have mainly focused on modulating the activity of T cells, while Natural Killer (NK) cells have only recently been taken into consideration. NK cells represent an attractive target for cancer immunotherapy owing to their innate capacity to eliminate malignant tumors in a non-Major Histocompatibility Complex (MHC) and non-tumor antigen-restricted manner. In this review, we analyze the mechanisms and efficacy of NK cells in the control of metastasis and we detail the immunosubversive strategies developed by metastatic cells to evade NK cell-mediated immunosurveillance. We also share current and cutting-edge clinical approaches aimed at unleashing the full anti-metastatic potential of NK cells, including the adoptive transfer of NK cells, boosting of NK cell activity, redirecting NK cell activity against metastatic cells and the release of evasion mechanisms dampening NK cell immunosurveillance. MDPI 2018-12-28 /pmc/articles/PMC6357056/ /pubmed/30597841 http://dx.doi.org/10.3390/cancers11010029 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lorenzo-Herrero, Seila
López-Soto, Alejandro
Sordo-Bahamonde, Christian
Gonzalez-Rodriguez, Ana P
Vitale, Massimo
Gonzalez, Segundo
NK Cell-Based Immunotherapy in Cancer Metastasis
title NK Cell-Based Immunotherapy in Cancer Metastasis
title_full NK Cell-Based Immunotherapy in Cancer Metastasis
title_fullStr NK Cell-Based Immunotherapy in Cancer Metastasis
title_full_unstemmed NK Cell-Based Immunotherapy in Cancer Metastasis
title_short NK Cell-Based Immunotherapy in Cancer Metastasis
title_sort nk cell-based immunotherapy in cancer metastasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357056/
https://www.ncbi.nlm.nih.gov/pubmed/30597841
http://dx.doi.org/10.3390/cancers11010029
work_keys_str_mv AT lorenzoherreroseila nkcellbasedimmunotherapyincancermetastasis
AT lopezsotoalejandro nkcellbasedimmunotherapyincancermetastasis
AT sordobahamondechristian nkcellbasedimmunotherapyincancermetastasis
AT gonzalezrodriguezanap nkcellbasedimmunotherapyincancermetastasis
AT vitalemassimo nkcellbasedimmunotherapyincancermetastasis
AT gonzalezsegundo nkcellbasedimmunotherapyincancermetastasis